Praxis Precision Medicines Inc
PRAX
Market Cap$1.15B
Close$
$13.37
79.4% downside
Current Fair Value
79.4% downsideOvervalued by 79.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.15 Billion |
|---|---|
| Enterprise Value | $1.01 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-18.69 |
| Beta | 2.74 |
| Outstanding Shares | 18,824,479 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -9.88 |
|---|---|
| PEG | 207.33 |
| Price to Sales | - |
| Price to Book Ratio | 2.95 |
| Enterprise Value to Revenue | 570.93 |
| Enterprise Value to EBIT | -7.6 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Praxis Precision Medicines Inc
2,020 employeesPraxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying in...